NVN Liquidation, Inc.

On July 17, 2023, NVN Liquidation, Inc. f/k/a Novan, Inc., filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and is no longer operating.

On September 27, 2023, substantially all of the assets of Novan, Inc. (not including certain assets of its wholly-owned subsidiary EPI Health, LLC listed below) were transferred to an affiliate of Ligand Pharmaceuticals, Incorporated.

Court filings and other information related to the NVN Liquidation Inc. f/k/a Novan, Inc.’s proceedings are available on a separate website administrated by the Company’s claims agent, KCC, at www.kccllc.net/novan. For additional information, please call 1-888-251-2954 (U.S./Canada), or +1-310-751-2614, or submit an inquiry at www.kccllc.net/novan/inquiry.

For Information related to Rhofade, visit:



Mayne Pharma
3301 Benson Drive, Suite 401
Raleigh, NC  27609 United States

To report suspected adverse reactions related to Rhofade, contact Mayne Pharma at 1-800-499-4468, us.medicalinformation@maynepharma.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For Information Related to Wynzora, visit:


For Information Related to Minolira, visit:


For Information Related to Cloderm, visit:


You are encouraged to report suspected adverse reactions related to Wynzora, Minolira or Cloderm to EPI Health at
1-843-965-8333 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.